Healthcare / BiotechnologyKOSDAQ
$501.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-40.6B · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-53.7%
↓Gross Margin
100.0%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-34003.6%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $94.8M · net income $-31.80B · FCF $-32.24B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $94.8M | $94.8M | $170.4M | — | — |
| Net Income | $-31.80B | $-31.80B | $-40.88B | $-53.40B | $-60.41B |
| EBITDA | $-26.89B | $-26.89B | $-36.47B | $-49.83B | $-57.17B |
| EPS | — | — | -2073.00 | -2702.00 | -3062.00 |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | -26596.5% | -26596.5% | -23497.6% | — | — |
| Net Margin | -33531.4% | -33531.4% | -23994.6% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.26 | 0.05 | 0.04 |
| Current Ratio | 2.65 | 2.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32.24B | $-32.24B | $-40.61B | $-50.55B | $-44.88B |
| Returns | |||||
| ROE | -53.7% | -53.7% | -98.1% | -71.3% | -50.5% |
| Valuation | |||||
| P/B | 0.28 | 0.28 | 0.56 | 0.50 | 0.66 |
| Growth & Yield | |||||
| Revenue Growth | -44.3% | -44.3% | — | — | — |
| EPS Growth | — | — | 23.3% | 11.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-67.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-2073.00 → n/d
Residual
-67.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.